Buy LGD-4033 Online
A selective androgen receptor modulator (SARM), LGD-4033LGD-4033 has not been approved for human clinical use by the U.S. Food and Drug Administration (FDA), but it is being studied as a pharmaceutical treatment for aging-related muscle wasting and weakness.
According to the World Anti-Doping Agency (WADA) Prohibited List, is LGD-4033 prohibited?
Yes, LGD-4033 is on the WADA Prohibited List under class S1.2 Other Anabolic Agents. All athletes, both in and out of competition, are prohibited at all times from using LGD-4033 or any other SARM.
How does LGD-0433 improve performance?
Athletes may abuse LGD-4033 for its anabolic, muscle-building effects because it has been shown to increase lean muscle mass. There are labs that produce LGD-4033 and sell it as a “research chemical,” despite the fact that it is not permitted in any medication anywhere in the world. This is a red flag, and athletes should steer clear of any product marketed for sport performance or muscle building that also claims to be “not for human consumption” or “research use only.”
Most notably, LGD-4033 is spiked or contaminated in some supplements-marketed products. Additionally, the label may or may not reflect this. Since the FDA has made it clear that LGD-4033 is not a legitimate dietary ingredient, it is against the law to sell it in supplements. The Food and Drug Administration (FDA) would classify any dietary supplement as an unapproved new drug and recommend that it be avoided.
Ligandrol for sale worldwide
In addition to the possibility of a positive test, LGD-4033’s short- and long-term effects are unknown because it has not been subjected to the clinical studies required to demonstrate its safety.
Until this point, we really do know that LGD-4033 causes a decline in the development of testosterone and different chemicals, so there is proof that it disturbs hormonal motioning in the body.
Ligandrol (VK5211, LGD-4033) is a novel nonsteroidal oral selective androgen receptor modulator (SARM) for the treatment of conditions like muscle wasting and osteoporosis. It was discovered by Ligand Pharmaceuticals and is currently being developed by Viking Therapeutics.[4][5] Ligandrol has also been found in racehorse samples and samples from the World Anti-Doping Agency (WADA).It can encourage muscle growth, similar to anabolic steroids. “SARMs have been shown to have better side effects than anabolic steroids, which may make them appealing to people who want an unfair advantage over their rivals.
History of Ligandrol The American company Ligand Pharmaceuticals was the one who initially developed Ligandrol, which is also known by the development codes LGD-4033 and VK5211 and by the name Anabolicum.2009 saw its patenting.
In 2013, the first human clinical trial’s findings, which showed that taking Ligandrol increased muscle mass without adding fat, were published.
The rights to the drug have since been licensed to Viking Therapeutics. It finished a clinical trial in 2018 that looked at Ligandrol for people over 65 who were healing from a hip fracture. Patients who took Ligandrol had significantly more muscle mass and were able to walk further than those who did not.
The medication has likewise been inspected for different circumstances, including as a potential therapy for malignant growth related weight reduction, broadened prostates, for patients who have a lessened capability of testicles and ovaries, and as an expected remedy for bosom disease.
The Australian Therapeutic Goods Administration (TGA) has not approved the sale of Ligandrol because it is still considered an experimental drug.
Benefits of Ligandrol
How it works Ligandrol is taken by mouth as a tablet in doses of 0.5 to 2 milligrams.
A selective androgen receptor modulator (SARM) is the name given to the medication by pharmacists. These medications tie at explicit destinations on skeletal muscles. They start a chain of events there that alter the expression of various genes in muscle cell DNA. The end result is increased muscle repair and growth.
Reviews
There are no reviews yet.